Cancer

Addition of elotuzumab ups PFS in refractory multiple myeloma

(HealthDay)—For patients with multiple myeloma in whom treatment with lenalidomide and a proteasome inhibitor has failed, progression-free survival (PFS) is longer in those receiving the immunostimulatory monoclonal antibody ...

Cancer

Blood cancer precursor found in 9/11 firefighters

A study in today's issue of JAMA Oncology reports that New York City firefighters exposed to the 9/11 World Trade Center disaster site face an increased risk for developing myeloma precursor disease (MGUS), which can lead ...

page 1 from 22

Multiple myeloma

Multiple myeloma (from myelo-, bone marrow), also known as MM, myeloma, plasma cell myeloma, or as Kahler's disease (after Otto Kahler) is a cancer of the white blood cells known as plasma cells, which produce antibodies.

These plasma cells, or B cells, are part of the immune system, formed in bone marrow, and numerous in lymphatics. Myeloma is incurable, but remissions may be induced with steroids, chemotherapy, thalidomide and stem cell transplants.

There were 15,270 cases diagnosed and 11,070 deaths in the United States in 2004, and an incidence of 4/100,000 worldwide. Median survival is 50–55 months. Chromosome diagnosis can separate patients into more or less favorable prognoses.

Myeloma is part of the broad group of diseases called hematological malignancies.

This text uses material from Wikipedia, licensed under CC BY-SA